Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 405,159 shares, a decrease of 41.7% from the October 13th total of 694,616 shares. Currently, 3.8% of the shares of the company are sold short. Based on an average daily trading volume, of 101,910 shares, the short-interest ratio is presently 4.0 days.

Protagonist Therapeutics (NASDAQ PTGX) opened at $16.96 on Tuesday. Protagonist Therapeutics has a twelve month low of $8.00 and a twelve month high of $26.36.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.40. The company had revenue of $8.78 million for the quarter. equities research analysts forecast that Protagonist Therapeutics will post -3.66 earnings per share for the current year.

In other Protagonist Therapeutics news, insider Richard S. Shames sold 2,017 shares of the stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $19.00, for a total transaction of $38,323.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider David Y. Liu sold 3,500 shares of the stock in a transaction on Monday, August 28th. The shares were sold at an average price of $15.00, for a total transaction of $52,500.00. Following the transaction, the insider now directly owns 5,500 shares in the company, valued at $82,500. The disclosure for this sale can be found here. Insiders have sold 10,716 shares of company stock worth $169,288 over the last three months.

Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in shares of Protagonist Therapeutics by 60.8% in the third quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after buying an additional 3,617 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Protagonist Therapeutics in the second quarter worth about $114,000. Teachers Advisors LLC lifted its stake in shares of Protagonist Therapeutics by 71.4% in the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock worth $183,000 after buying an additional 6,757 shares in the last quarter. California State Teachers Retirement System lifted its stake in shares of Protagonist Therapeutics by 8.5% in the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after buying an additional 1,300 shares in the last quarter. Finally, First Manhattan Co. purchased a new position in shares of Protagonist Therapeutics in the third quarter worth about $293,000. 39.73% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have issued reports on PTGX. Zacks Investment Research raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Saturday. ValuEngine downgraded shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 11th. BMO Capital Markets decreased their price objective on shares of Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 19th. Finally, BTIG Research began coverage on shares of Protagonist Therapeutics in a report on Friday, July 21st. They set a “buy” rating and a $36.00 price objective on the stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/14/protagonist-therapeutics-inc-ptgx-short-interest-down-41-7-in-october.html.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Stock Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related stocks with our FREE daily email newsletter.